Earnings Feed
Start Free
Coherus Oncology, Inc.·4

Jun 9, 6:41 PM ET

O'Donnell-Tormey Jill 4

Research Summary

AI-generated summary

Updated

Coherus (CHRS) Director Jill O'Donnell-Tormey Receives Awards

What Happened
Jill O'Donnell-Tormey, a director of Coherus Oncology (CHRS), received equity awards on 2026-06-05: 30,000 restricted stock units (RSUs) and a 60,000-share derivative award (grant reported at $0.00, i.e., no cash paid). These are grants (not open‑market purchases or sales) and are typically part of director compensation.

Key Details

  • Transaction date: June 5, 2026; Form 4 filed June 9, 2026 (filed within the required two business days).
  • Consideration: $0.00 per share (award/grant). Reported amounts: 30,000 (RSUs) + 60,000 (derivative award).
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Footnotes:
    • F1 (30,000 RSUs): Each RSU converts to one share; 100% vest on the one‑year anniversary of June 3, 2026 (i.e., June 3, 2027), subject to continued service.
    • F2 (60,000 derivative award): Underlying shares vest and become exercisable 100% on June 3, 2027, subject to continued service.
  • Transaction code: A = Award/Grant.

Context
RSUs and derivative awards are common forms of director compensation and do not involve an immediate cash outlay or market sale. The derivative award appears to be an option-like grant that will become exercisable when it vests. These grants reflect compensation timing and vesting conditions rather than an expressed buy/sell sentiment.